🇺🇸 FDA
Patent

US 7482351

4-pyrimidineamine compounds and their uses as anti-proliferative agents

granted A61PA61P35/00A61P35/04

Quick answer

US patent 7482351 (4-pyrimidineamine compounds and their uses as anti-proliferative agents) held by Rigel Pharmaceuticals, Inc. expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61P, A61P35/00, A61P35/04